These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8549307)

  • 41. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 43. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

  • 44. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 45. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 46. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
    Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
    Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
    Yoshizumi S; Takahashi Y; Murata M; Domon H; Furuya N; Ishii Y; Matsumoto T; Ohno A; Tateda K; Miyazaki S; Yamaguchi K
    J Antimicrob Chemother; 2001 Jul; 48(1):137-40. PubMed ID: 11418525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-analyses on the prevention and treatment of respiratory tract infections.
    Siempos II; Dimopoulos G; Falagas ME
    Infect Dis Clin North Am; 2009 Jun; 23(2):331-53. PubMed ID: 19393913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapeutic efficacy of intravenous and oral ciprofloxacin in experimental murine infections.
    Nishino T; Obana Y
    Chemotherapy; 1996; 42(2):140-5. PubMed ID: 8697889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of the fluoroquinolones.
    Guay DR
    Pharmacotherapy; 1992; 12(6 Pt 2):71S-85S. PubMed ID: 1480503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levofloxacin failure in a patient with pneumococcal pneumonia.
    Empey PE; Jennings HR; Thornton AC; Rapp RP; Evans ME
    Ann Pharmacother; 2001 Jun; 35(6):687-90. PubMed ID: 11408985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
    Harazim H; Wimmer J; Mittermayer HP
    Drugs; 1987; 34 Suppl 1():71-3. PubMed ID: 3481331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New uses for new and old quinolones and the challenge of resistance.
    Hooper DC
    Clin Infect Dis; 2000 Feb; 30(2):243-54. PubMed ID: 10671323
    [No Abstract]   [Full Text] [Related]  

  • 58. Fluoroquinolones as treatment for patients with lower respiratory tract infections caused by Streptococcus pneumoniae.
    Amyes SG; Thomson CJ
    J Antimicrob Chemother; 1998 Sep; 42(3):398-9. PubMed ID: 9786483
    [No Abstract]   [Full Text] [Related]  

  • 59. [Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].
    Jpn J Antibiot; 1994 Oct; 47(10):1241-58. PubMed ID: 7807686
    [No Abstract]   [Full Text] [Related]  

  • 60. Ofloxacin in respiratory tract infection. A review of the results of clinical trials in Japan.
    Saito A; Katsu M; Saito A; Soejima R
    Drugs; 1987; 34 Suppl 1():83-9. PubMed ID: 3325261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.